Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared a post on X:
“Perioperative Enfortumab Vedotin and pembrolizumab beats neoadjuvant chemotherapy & cystectomy in muscle invasive bladder cancer. We’re moving towards a bladder surgery sparing strategies using EVP. This is another step towards curing bladder cancer.”
More posts featuring Thomas Powles on OncoDaily.